Terms: = Prostate cancer AND MUC16, CA125, CA-125 AND Treatment
39 results:
1. Endoplasmic reticulum stress-related genes as prognostic and immunogenic biomarkers in prostate cancer.
Wan L; Fan Y; Wu T; Liu Y; Zhang R; Chen S; Zhao C; Xue Y
Eur J Med Res; 2024 Apr; 29(1):242. PubMed ID: 38643190
[TBL] [Abstract] [Full Text] [Related]
2. Tumour Marker Requisition Pattern in a Tertiary Care Centre of Eastern Nepal.
Niraula A; Gelal B; Chaudhari RK; Das BK; Lamsal M
Kathmandu Univ Med J (KUMJ); 2022; 20(80):422-426. PubMed ID: 37795716
[TBL] [Abstract] [Full Text] [Related]
3. Electrochemical aptasensor based on the engineered core-shell MOF nanostructures for the detection of tumor antigens.
Khan S; Cho WC; Sepahvand A; Haji Hosseinali S; Hussain A; Nejadi Babadaei MM; Sharifi M; Falahati M; Jaragh-Alhadad LA; Ten Hagen TLM; Li X
J Nanobiotechnology; 2023 Apr; 21(1):136. PubMed ID: 37101280
[TBL] [Abstract] [Full Text] [Related]
4. 68 Ga-prostate-Specific Membrane Antigen PET/CT in Ovarian Tumors : Potential to Differentiate Benign and Malignant Tumors Before Surgery: A Preliminary Report.
Kunikowska J; Bizoń M; Pełka K; Derlatka P; Olszewski M; Królicki L
Clin Nucl Med; 2023 Feb; 48(2):e60-e66. PubMed ID: 36512649
[TBL] [Abstract] [Full Text] [Related]
5. Nanotechnological approaches for diagnosis and treatment of ovarian cancer: a review of recent trends.
Ding H; Zhang J; Zhang F; Xu Y; Liang W; Yu Y
Drug Deliv; 2022 Dec; 29(1):3218-3232. PubMed ID: 36259505
[TBL] [Abstract] [Full Text] [Related]
6. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of prostate cancer.
Zhang P; An Z; Sun C; Xu Y; Zhang Z
Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
[TBL] [Abstract] [Full Text] [Related]
7. RBAC and Its Role with the Immune System.
Pescatore F; Prestano C; Kichikova M
Altern Ther Health Med; 2022 Jan; 28(1):8-10. PubMed ID: 35120333
[TBL] [Abstract] [Full Text] [Related]
8. Nanotechnology in ovarian cancer: Diagnosis and treatment.
Barani M; Bilal M; Sabir F; Rahdar A; Kyzas GZ
Life Sci; 2021 Feb; 266():118914. PubMed ID: 33340527
[TBL] [Abstract] [Full Text] [Related]
9. Cabazitaxel - A treatment Option in Recurrent Platinum-resistant Ovarian cancer.
Madsen CV; Adimi P; Jakobsen A; Steffensen KD
Anticancer Res; 2020 Sep; 40(9):5255-5261. PubMed ID: 32878814
[TBL] [Abstract] [Full Text] [Related]
10. Tumour markers and their utility in imaging of abdominal and pelvic malignancies.
Lahoud RM; O'Shea A; El-Mouhayyar C; Atre ID; Eurboonyanun K; Harisinghani M
Clin Radiol; 2021 Feb; 76(2):99-107. PubMed ID: 32861463
[TBL] [Abstract] [Full Text] [Related]
11. A 5-year follow-up of primary seminal vesicle adenocarcinoma: A case report.
Yin T; Jiang Y
Medicine (Baltimore); 2018 Oct; 97(41):e12600. PubMed ID: 30313047
[TBL] [Abstract] [Full Text] [Related]
12. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality.
Kamal R; Hamed S; Mansour S; Mounir Y; Abdel Sallam S
Br J Radiol; 2018 Oct; 91(1090):20170571. PubMed ID: 30102555
[TBL] [Abstract] [Full Text] [Related]
13. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
14. [Clinicopathological features of primary seminal vesicle adenocarcinoma: A report of 4 cases and review of the literature].
Guo JN; Li H; Hu ZD; Liang EL; Chang JW
Zhonghua Nan Ke Xue; 2017 Jul; 23(7):639-645. PubMed ID: 29723459
[TBL] [Abstract] [Full Text] [Related]
15. The bimanual ovarian palpation examination in the prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications.
Doroudi M; Kramer BS; Pinsky PF
J Med Screen; 2017 Dec; 24(4):220-222. PubMed ID: 27903809
[TBL] [Abstract] [Full Text] [Related]
16. [Immunoassay of nine serological tumor markers on hydrogel-based microchip].
Zubcova ZhI; Savvateeva EN; Butvilovskaia VI; Cybul'skaia MV; Chechetkin VR; Samokhina LO; Vinnitskiĭ LI; Maslennikov VV; Reznikov IuP; Zasedatelev AS; Rubina AIu
Bioorg Khim; 2013; 39(6):693-704. PubMed ID: 25696931
[TBL] [Abstract] [Full Text] [Related]
17. Serum tumor markers and PET/CT imaging for tumor recurrence detection.
Kruse V; Cocquyt V; Borms M; Maes A; Van de Wiele C
Ann Nucl Med; 2013 Feb; 27(2):97-104. PubMed ID: 23420146
[TBL] [Abstract] [Full Text] [Related]
18. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
Sandhu SK; Papadopoulos K; Fong PC; Patnaik A; Messiou C; Olmos D; Wang G; Tromp BJ; Puchalski TA; Balkwill F; Berns B; Seetharam S; de Bono JS; Tolcher AW
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1041-50. PubMed ID: 23385782
[TBL] [Abstract] [Full Text] [Related]
19. Serum levels of cancer biomarkers in diabetic and non-diabetic proteinuric patients: a preliminary study.
Turgutalp K; Ozhan O; Helvacı I; Ata A; Arican A; Boztepe B; Kıykım A
Clin Chem Lab Med; 2013 Apr; 51(4):889-95. PubMed ID: 23314541
[TBL] [Abstract] [Full Text] [Related]
20. Tumor markers in clinical practice: a review focusing on common solid cancers.
Duffy MJ
Med Princ Pract; 2013; 22(1):4-11. PubMed ID: 22584792
[TBL] [Abstract] [Full Text] [Related]
[Next]
